Global Big Pharma Partnering Terms and Agreements 2020-2024

Global Big Pharma Partnering Terms and Agreements 2020 to 2024 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of 2,022 Big Pharma agreements announced in the life sciences since 2020.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

Online deal records of Big Pharma deals as disclosed by the deal parties are included in a directory format by:

• Company A-Z
• Stage of development
• Deal type
• Therapy focus
• Technology type
• In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
• The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2020, including details of headline, upfront, milestone and royalty terms.
• Chapter 3 provides a review of the leading Big Pharma deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
• Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.
• Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2020, where a contract document is available in the public domain. Each deal title links via hyperlink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2020. The chapter is organized by specific technology type. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
• A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
• The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2020.
• In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

Key benefits

Global Big Pharma Partnering Terms and Agreements 2020-2024 provides the reader with the following key benefits:

• In-depth understanding of Big Pharma deal trends since 2020
• Access to headline, upfront, milestone and royalty data
• Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
• Identify most active Big Pharma dealmakers since 2020
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

• Global Big Pharma Partnering Terms and Agreements 2020-2024 is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

Big Pharma Partnering Terms and Agreements includes:

• Trends in Big Pharma dealmaking in the biopharma industry since 2020
• Access to headline, upfront, milestone and royalty data
• Access to Big Pharma contract documents
• Leading Big Pharma deals by value since 2020
• Most active Big Pharma dealmakers since 2020

In Global Big Pharma Partnering Terms and Agreements 2020-2024, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
• The Global Big Pharma Partnering Terms and Agreements 2020-2024 report provides comprehensive access to available Big Pharma deals and contract documents.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?